Investors: Don’t Buy Canopy Growth Corp (TSX:WEED) Until This Happens

Potential marijuana legalization in the United States could send Canopy Growth Corp (TSX:WEED)(NYSE:CGC) shares soaring, but it won’t be an easy task to dominate the market.

| More on:
caution

It’s easy to see why investors are excited about Canopy Growth (TSX:WEED)(NYSE:CGC) and the marijuana space in general.

The company projects the medical marijuana industry alone in Canada is worth $3 billion a year, with the recreational market worth between $5 and $9 billion annually. Now that cannabis is legal, there’s also ample opportunity to enter ancillary markets like cannabis-infused drinks, edibles, animal health, and sleep aids in the future.

But at the same time, critics say all this potential is easily priced into Canopy’s stock price. As I type this, Canopy’s share price is just under $42, which translates into a market cap of $14.2 billion. It has this valuation, despite selling just $93.7 million worth of product over the last year.

Now Canopy is expanding around the world. It currently has operations in nations like Germany, Brazil, and Australia, and plans expansions into other markets like South Africa and Colombia. And although most of these nations don’t use cannabis as much as we do in Canada on a per capita basis, there are still a lot of people around the world who do consume it. And investors have to like that Canopy is taking steps to seize opportunities around the world.

Still, I’m a firm believer that Canopy — and its peers — simply can’t justify their sky-high valuations unless they have a clear path to the largest cannabis market in the world. The United States is the real prize here. Even a small portion of the U.S. market could be a massive win for Canopy and other pot stocks.

Can Canopy expand in the U.S.?

Unfortunately, as we’ve seen in Canada, legalizing marijuana isn’t a simple process. We’re now close to two months into legalization here and retail stores are still dealing with a plethora of shortages and other issues. Many consumers are just continuing to use their dealers as if nothing has changed.

And this is in Canada, which is a much smaller economy than the United States.

Investors must remember that marijuana is already legal in ten states as well as the District of Colombia. It’s also legal for medical use in 33 states. A large network of growers has already popped up in the United States, companies run by entrepreneurs who would relish the opportunity to supply the rest of the country. It’s not going to be easy for Canopy to become a big player in this market.

Finally, although polls indicate a majority of U.S. adults would like to see marijuana legalized across the country, there’s virtually zero chance of it happening until a Democrat takes over the White House. And many speculate a Democrat president would have greater priorities than legalization, which has staunch opposition from a vocal minority.

In short, it’s going to be extremely tough for Canopy to crack the U.S. market. But without that potential win, it’s going to be difficult for the company to justify its massive valuation today.

The bottom line

If Canopy was a $1 billion or even a $5 billion company today, I’d be much more comfortable investing in the stock. But it’s not. At its peak, Canopy’s market cap was just over $26 billion. Today, shares are worth $14 billion.

That’s still too much, at least in this analyst’s opinion. For Canopy to justify its valuation, it must get a major win like potential expansion into the U.S. That should be enough to send shares much higher. But even then, cracking the U.S. market is going to be a tough journey.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nelson Smith has no position in any stocks mentioned.   

More on Investing

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Investing

3 Roaring Stocks to Hold for the Next 20 Years

These top TSX stocks are excellent long-term buys, given their multi-year growth potential and solid underlying businesses.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »

Businessman holding AI cloud
Tech Stocks

Could Investing $20,000 in Nvidia Make You a Millionaire?

Nvidia stock has made investors millionaires in the last 10 years. Is it too late to invest to become a…

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

money cash dividends
Stocks for Beginners

Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

If you're looking for cheap stocks, these three have a huge future ahead of them, all while costing far less…

Read more »